Advertisement

Atherosclerotic Cardiovascular Risk Stratification in the Rheumatic Diseases:

An Integrative, Multiparametric Approach

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nurmohamed M.T.
        • Heslinga M.
        • Kitas G.D.
        Cardiovascular comorbidity in rheumatic diseases.
        Nat Rev Rheumatol. 2015; 11: 693-704
        • Avina-Zubieta J.A.
        • Thomas J.
        • Sadatsafavi M.
        • et al.
        Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.
        Ann Rheum Dis. 2012; 71: 1524-1529
        • Restivo V.
        • Candiloro S.
        • Daidone M.
        • et al.
        Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus.
        Autoimmun Rev. 2022; 21: 102925
        • Semb A.G.
        • Ikdahl E.
        • Wibetoe G.
        • et al.
        Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.
        Nat Rev Rheumatol. 2020; 16: 361-379
        • Agca R.
        • Heslinga S.C.
        • Rollefstad S.
        • et al.
        EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
        Ann Rheum Dis. 2017; 76: 17-28
        • Karczewski K.J.
        • Dudley J.T.
        • Kukurba K.R.
        • et al.
        Systematic functional regulatory assessment of disease-associated variants.
        Proc Natl Acad Sci U S A. 2013; 110: 9607-9612
        • Paakkanen R.
        • Lokki M.L.
        • Seppänen M.
        • et al.
        Proinflammatory HLA-DRB1∗01-haplotype predisposes to ST-elevation myocardial infarction.
        Atherosclerosis. 2012; 221: 461-466
        • Gonzalez-Gay M.A.
        • Gonzalez-Juanatey C.
        • Lopez-Diaz M.J.
        • et al.
        HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
        Arthritis Rheum. 2007; 57: 125-132
        • Ferraz-Amaro I.
        • Winchester R.
        • Gregersen P.K.
        • et al.
        Coronary Artery Calcification and Rheumatoid Arthritis: Lack of Relationship to Risk Alleles for Coronary Artery Disease in the General Population.
        Arthritis Rheumatol. 2017; 69: 529-541
        • López-Mejías R.
        • Corrales A.
        • Vicente E.
        • et al.
        Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.
        Sci Rep. 2017; 7: 40303
        • Karpouzas G.A.
        • Bui V.L.
        • Ronda N.
        • et al.
        Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights.
        Expert Rev Clin Immunol. 2021; 17: 355-374
        • Giannelou M.
        • Mavragani C.P.
        Cardiovascular disease in systemic lupus erythematosus: A comprehensive update.
        J Autoimmun. 2017; 82: 1-12
        • Escalante A.
        • Haas R.W.
        • del Rincón I.
        Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation.
        Arch Intern Med. 2005; 165: 1624-1629
        • Kremers H.M.
        • Nicola P.J.
        • Crowson C.S.
        • et al.
        Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.
        Arthritis Rheum. 2004; 50: 3450-3457
        • Giles J.T.
        • Allison M.
        • Blumenthal R.S.
        • et al.
        Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics.
        Arthritis Rheum. 2010; 62: 3173-3182
        • Gonzalez A.
        • Maradit Kremers H.
        • Crowson C.S.
        • et al.
        Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?.
        Ann Rheum Dis. 2008; 67: 64-69
        • Myasoedova E.
        • Crowson C.S.
        • Kremers H.M.
        • et al.
        Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
        Ann Rheum Dis. 2011; 70: 482-487
        • Karpouzas G.A.
        • Ormseth S.R.
        • Ronda N.
        • et al.
        Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis.
        J Autoimmun. 2022; 129: 102815
        • Holmqvist M.
        • Ljung L.
        • Askling J.
        Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks.
        Ann Rheum Dis. 2017; 76: 1642-1647
        • Edwards C.J.
        • Syddall H.
        • Goswami R.
        • et al.
        The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men.
        Heart. 2007; 93: 1263-1267
        • López-Longo F.J.
        • Oliver-Miñarro D.
        • de la Torre I.
        • et al.
        Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis.
        Arthritis Rheum. 2009; 61: 419-424
        • Cambridge G.
        • Acharya J.
        • Cooper J.A.
        • et al.
        Antibodies to citrullinated peptides and risk of coronary heart disease.
        Atherosclerosis. 2013; 228: 243-246
        • Karpouzas G.A.
        • Malpeso J.
        • Choi T.Y.
        • et al.
        Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease.
        Ann Rheum Dis. 2014; 73: 1797-1804
        • Karpouzas G.A.
        • Ormseth S.R.
        • Hernandez E.
        • et al.
        Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis.
        Arthritis Rheumatol. 2020; 72: 400-408
        • Karpouzas G.A.
        • Ormseth S.R.
        • Hernandez E.
        • et al.
        Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions.
        Arthritis Rheumatol. 2020; 72: 1467-1475
        • Liuzzo G.
        • Goronzy J.J.
        • Yang H.
        • et al.
        Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
        Circulation. 2000; 101: 2883-2888
        • Crowson C.S.
        • Matteson E.L.
        • Roger V.L.
        • et al.
        Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis.
        Am J Cardiol. 2012; 110: 420-424
        • Arts E.E.
        • Popa C.
        • Den Broeder A.A.
        • et al.
        Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis.
        Ann Rheum Dis. 2015; 74: 668-674
        • Esdaile J.M.
        • Abrahamowicz M.
        • Grodzicky T.
        • et al.
        Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.
        Arthritis Rheum. 2001; 44: 2331-2337
        • Crowson C.S.
        • Gabriel S.E.
        • Semb A.G.
        • et al.
        Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.
        Rheumatology (Oxford). 2017; 56: 1102-1110
        • Crowson C.S.
        • Rollefstad S.
        • Kitas G.D.
        • et al.
        Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.
        PLoS One. 2017; 12: e0174656
        • Corrales A.
        • González-Juanatey C.
        • Peiró M.E.
        • et al.
        Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study.
        Ann Rheum Dis. 2014; 73: 722-727
        • Skaggs B.J.
        • Grossman J.
        • Sahakian L.
        • et al.
        A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.
        ACR open Rheumatol. 2021; 3: 209-220
        • Curtis J.R.
        • Xie F.
        • Crowson C.S.
        • et al.
        Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
        Arthritis Res Ther. 2020; 22: 282
        • Sade L.E.
        • Akdogan A.
        Imaging for screening cardiovascular involvement in patients with systemic rheumatologic diseases: more questions than answers.
        Eur Heart J Cardiovasc Imaging. 2019; 20: 967-978
        • Evans M.R.
        • Escalante A.
        • Battafarano D.F.
        • et al.
        Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis.
        Arthritis Rheum. 2011; 63: 1211-1220
        • Den Ruijter H.M.
        • Peters S.A.
        • Anderson T.J.
        • et al.
        Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.
        JAMA. 2012; 308: 796-803
        • Mach F.
        • Baigent C.
        • Catapano A.L.
        • et al.
        2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur Heart J. 2020; 41: 111-188
        • Gepner A.D.
        • Young R.
        • Delaney J.A.
        • et al.
        Comparison of Carotid Plaque Score and Coronary Artery Calcium Score for Predicting Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis.
        J Am Heart Assoc. 2017; 6
        • Mortensen M.B.
        • Fuster V.
        • Muntendam P.
        • et al.
        A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study.
        J Am Coll Cardiol. 2016; 68: 881-891
        • Svanteson M.
        • Rollefstad S.
        • Kløw N.E.
        • et al.
        Associations between coronary and carotid artery atherosclerosis in patients with inflammatory joint diseases.
        RMD Open. 2017; 3: e000544
        • Choi H.
        • Uceda D.E.
        • Dey A.K.
        • et al.
        Application of Non-invasive Imaging in Inflammatory Disease Conditions to Evaluate Subclinical Coronary Artery Disease.
        Curr Rheumatol Rep. 2019; 22: 1
        • Newby D.E.
        • Adamson P.D.
        • Berry C.
        • et al.
        Coronary CT Angiography and 5-Year Risk of Myocardial Infarction.
        N Engl J Med. 2018; 379: 924-933
        • Arnett D.K.
        • Blumenthal R.S.
        • Albert M.A.
        • et al.
        2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2019; 140: e596-e646
        • Byun Y.S.
        • Yang X.
        • Bao W.
        • et al.
        Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
        J Am Coll Cardiol. 2017; 69: 147-158
        • Salonen J.T.
        • Ylä-Herttuala S.
        • Yamamoto R.
        • et al.
        Autoantibody against oxidised LDL and progression of carotid atherosclerosis.
        Lancet. 1992; 339: 883-887
        • Lopez L.R.
        • Simpson D.F.
        • Hurley B.L.
        • et al.
        OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
        Ann N Y Acad Sci. 2005; 1051: 313-322
        • Suciu C.F.
        • Prete M.
        • Ruscitti P.
        • et al.
        Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders.
        Autoimmun Rev. 2018; 17: 366-375
        • Svenungsson E.
        • Jensen-Urstad K.
        • Heimbürger M.
        • et al.
        Risk factors for cardiovascular disease in systemic lupus erythematosus.
        Circulation. 2001; 104: 1887-1893
        • Grönwall C.
        • Reynolds H.
        • Kim J.K.
        • et al.
        Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus.
        Clin Immunol. 2014; 153: 1-7
        • Fesmire J.
        • Wolfson-Reichlin M.
        • Reichlin M.
        Effects of autoimmune antibodies anti-lipoprotein lipase, anti-low density lipoprotein, and anti-oxidized low density lipoprotein on lipid metabolism and atherosclerosis in systemic lupus erythematosus.
        Rev Bras Reumatol. 2010; 50: 539-551
        • Nowak B.
        • Madej M.
        • Łuczak A.
        • et al.
        Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
        Adv Clin Exp Med. 2016; 25: 43-50
        • Adorni M.P.
        • Ronda N.
        • Bernini F.
        • et al.
        High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.
        Cells. 2021; 10
        • Soria-Florido M.T.
        • Schröder H.
        • Grau M.
        • et al.
        High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis.
        Atherosclerosis. 2020; 302: 36-42
        • Voloshyna I.
        • Modayil S.
        • Littlefield M.J.
        • et al.
        Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages.
        Exp Biol Med (Maywood). 2013; 238: 1192-1197
        • Arida A.
        • Protogerou A.D.
        • Kitas G.D.
        • et al.
        Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.
        Int J Mol Sci. 2018; 19
        • Skeoch S.
        • Bruce I.N.
        Atherosclerosis in rheumatoid arthritis: is it all about inflammation?.
        Nat Rev Rheumatol. 2015; 11: 390-400
        • López P.
        • Rodríguez-Carrio J.
        • Martínez-Zapico A.
        • et al.
        IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile.
        Rheumatology (Oxford). 2020; 59: 407-417
        • Xing H.
        • Pang H.
        • Du T.
        • et al.
        Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus.
        Front Immunol. 2021; 12: 622216
        • Rajkomar A.
        • Dean J.
        • Kohane I.
        Machine Learning in Medicine.
        N Engl J Med. 2019; 380: 1347-1358
        • Badillo S.
        • Banfai B.
        • Birzele F.
        • et al.
        An Introduction to Machine Learning.
        Clin Pharmacol Ther. 2020; 107: 871-885
        • Khanna N.N.
        • Jamthikar A.D.
        • Gupta D.
        • et al.
        Rheumatoid Arthritis: Atherosclerosis Imaging and Cardiovascular Risk Assessment Using Machine and Deep Learning-Based Tissue Characterization.
        Curr Atheroscler Rep. 2019; 21: 7
        • Triantafyllidis A.
        • Kondylakis H.
        • Katehakis D.
        • et al.
        Deep Learning in mHealth for Cardiovascular Disease, Diabetes, and Cancer: Systematic Review.
        JMIR Mhealth Uhealth. 2022; 10: e32344
        • Konstantonis G.
        • Singh K.V.
        • Sfikakis P.P.
        • et al.
        Cardiovascular disease detection using machine learning and carotid/femoral arterial imaging frameworks in rheumatoid arthritis patients.
        Rheumatol Int. 2022; 42: 215-239
        • Navarini L.
        • Sperti M.
        • Currado D.
        • et al.
        A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis.
        Rheumatology (Oxford). 2020; 59: 1767-1769
        • Bartoloni E.
        • Baldini C.
        • Ferro F.
        • et al.
        Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?.
        Clin Exp Rheumatol. 2019; 37 (Suppl 118(3)): 133-139
        • Okada D.R.
        • Xie E.
        • Assis F.
        • et al.
        Regional abnormalities on cardiac magnetic resonance imaging and arrhythmic events in patients with cardiac sarcoidosis.
        J Cardiovasc Electrophysiol. 2019; 30: 1967-1976
        • Katsushika S.
        • Kodera S.
        • Nakamoto M.
        • et al.
        Deep Learning Algorithm to Detect Cardiac Sarcoidosis From Echocardiographic Movies.
        Circ J. 2021; 86: 87-95
        • Drosos G.C.
        • Vedder D.
        • Houben E.
        • et al.
        EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
        Ann Rheum Dis. 2022; 81: 768-779
        • Visseren F.L.J.
        • Mach F.
        • Smulders Y.M.
        • et al.
        ESC Guidelines on cardiovascular disease prevention in clinical practice.
        Eur Heart J. 2021; 42: 3227-3337
      1. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.
        Eur Heart J. 2021; 42: 2439-2454
      2. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.
        Eur Heart J. 2021; 42: 2455-2467
        • Goff Jr., D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • et al.
        ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2935-2959
        • Aviña-Zubieta J.A.
        • Choi H.K.
        • Sadatsafavi M.
        • et al.
        Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.
        Arthritis Rheum. 2008; 59: 1690-1697
        • Radovits B.J.
        • Fransen J.
        • Al Shamma S.
        • et al.
        Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis.
        Arthritis Care Res (Hoboken). 2010; 62: 362-370
        • Nicola P.J.
        • Maradit-Kremers H.
        • Roger V.L.
        • et al.
        The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
        Arthritis Rheum. 2005; 52: 412-420
        • Holmqvist M.E.
        • Wedrén S.
        • Jacobsson L.T.
        • et al.
        Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006.
        J Intern Med. 2010; 268: 578-585
        • Myasoedova E.
        • Gabriel S.E.
        • Matteson E.L.
        • et al.
        Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?.
        J Rheumatol. 2017; 44: 732-739
        • Kerola A.M.
        • Nieminen T.V.
        • Virta L.J.
        • et al.
        No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.
        Clin Exp Rheumatol. 2015; 33: 391-398
        • Barbhaiya M.
        • Feldman C.H.
        • Chen S.K.
        • et al.
        Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients.
        Arthritis Care Res (Hoboken). 2020; 72: 1431-1439
        • Hermansen M.L.
        • Lindhardsen J.
        • Torp-Pedersen C.
        • et al.
        The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study.
        Rheumatology (Oxford). 2017; 56: 709-715
        • Polachek A.
        • Touma Z.
        • Anderson M.
        • et al.
        Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.
        Arthritis Care Res (Hoboken). 2017; 69: 67-74
        • Mathieu S.
        • Soubrier M.
        Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis.
        Ann Rheum Dis. 2019; 78: e57
        • Kim J.
        • Choi I.A.
        SAT0321 cardiovascular events in spondyloarthritis : a meta-analysis.
        Ann Rheum Dis. 2019; 78: 1239
        • Cen X.
        • Feng S.
        • Wei S.
        • et al.
        Systemic sclerosis and risk of cardiovascular disease: A PRISMA-compliant systemic review and meta-analysis of cohort studies.
        Medicine (Baltimore). 2020; 99: e23009
        • Yong W.C.
        • Sanguankeo A.
        • Upala S.
        Association between primary Sjögren's syndrome, cardiovascular and cerebrovascular disease: a systematic review and meta-analysis.
        Clin Exp Rheumatol. 2018; 36 (Suppl 112(3)): 190-197
        • Houben E.
        • Penne E.L.
        • Voskuyl A.E.
        • et al.
        Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.
        Rheumatology (Oxford). 2018; 57: 555-562
        • de Boysson H.
        • Aouba A.
        An Updated Review of Cardiovascular Events in Giant Cell Arteritis.
        J Clin Med. 2022; 11
        • Kim H.
        • Barra L.
        Ischemic complications in Takayasu's arteritis: A meta-analysis.
        Semin Arthritis Rheum. 2018; 47: 900-906
        • Schieir O.
        • Tosevski C.
        • Glazier R.H.
        • et al.
        Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.
        Ann Rheum Dis. 2017; 76: 1396-1404
        • Karpouzas G.A.
        • Estis J.
        • Rezaeian P.
        • et al.
        High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis.
        Rheumatology (Oxford). 2018; 57: 1080-1088
        • Hromádka M.
        • Seidlerová J.
        • Baxa J.
        • et al.
        Relationship between hsTnI and coronary stenosis in asymptomatic women with rheumatoid arthritis.
        BMC Cardiovasc Disord. 2016; 16: 184
        • Bradham W.S.
        • Bian A.
        • Oeser A.
        • et al.
        High-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammation.
        PloS one. 2012; 7: e38930
        • Colaco K.
        • Lee K.A.
        • Akhtari S.
        • et al.
        Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study.
        Arthritis Rheumatol. 2022; 74: 1184-1192
        • Zhou W.
        • Abdelrahman K.M.
        • Dey A.K.
        • et al.
        Association Among Noncalcified Coronary Burden, Fractional Flow Reserve, and Myocardial Injury in Psoriasis.
        J Am Heart Assoc. 2020; 9: e017417
        • Divard G.
        • Abbas R.
        • Chenevier-Gobeaux C.
        • et al.
        High-sensitivity cardiac troponin T is a biomarker for atherosclerosis in systemic lupus erythematous patients: a cross-sectional controlled study.
        Arthritis Res Ther. 2017; 19: 132
        • Mirjafari H.
        • Welsh P.
        • Verstappen S.M.
        • et al.
        N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR).
        Ann Rheum Dis. 2014; 73: 684-690
        • Goldenberg D.
        • Miller E.
        • Perna M.
        • et al.
        Association of N-terminal pro-brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus.
        Arthritis Rheum. 2012; 64: 316-317
        • Anania C.
        • Gustafsson T.
        • Hua X.
        • et al.
        Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.
        Arthritis Res Ther. 2010; 12: R214
        • Ahmed H.M.
        • Youssef M.
        • Mosaad Y.M.
        Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis.
        Clin Rheumatol. 2010; 29: 1237-1243
        • Cinoku I.
        • Mavragani C.P.
        • Tellis C.C.
        • et al.
        Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?.
        Clin Exp Rheumatol. 2018; 36 (Suppl 112(3)): 61-67
        • Karpouzas G.A.
        • Ormseth S.R.
        • Hernandez E.
        • et al.
        Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis.
        Semin Arthritis Rheum. 2021; 51: 20-27
        • Sánchez-Pérez H.
        • Quevedo-Abeledo J.C.
        • de Armas-Rillo L.
        • et al.
        Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis.
        Rheumatology (Oxford). 2020; 59: 2847-2856
        • Tejera-Segura B.
        • Macía-Díaz M.
        • Machado J.D.
        • et al.
        HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
        Arthritis Res Ther. 2017; 19: 113
        • Chang C.K.
        • Cheng W.C.
        • Ma W.L.
        • et al.
        The Potential Role of Electronegative High-Density Lipoprotein H5 Subfraction in RA-Related Atherosclerosis.
        Int J Mol Sci. 2021; 22
        • Karpouzas G.
        • Papotti B.
        • Ormseth S.
        • et al.
        OP0136 SERUM CHOLESTEROL LOADING CAPACITY ON MACROPHAGES AND INTERACTIONS WITH TREATMENTS ON CORONARY ATHEROSCLEROSIS BURDEN AND EVENT RISK IN RHEUMATOID ARTHRITIS.
        Ann Rheum Dis. 2022; 81: 87
        • Karpouzas G.
        • Papotti B.
        • Ormseth S.
        • et al.
        POS0596 serum cholesterol loading capacity on macrophages is linked to oxidized low-density lipoprotein and regulated by seropositivity and c-reactive protein in patients with rheumatoid arthritis.
        Ann Rheum Dis. 2022; 81: 565
        • Chang C.Y.
        • Chen C.H.
        • Chen Y.M.
        • et al.
        Association between Negatively Charged Low-Density Lipoprotein L5 and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients.
        J Clin Med. 2019; 8
        • García-Gómez C.
        • Martín-Martínez M.A.
        • Fernández-Carballido C.
        • et al.
        Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project.
        Clin Exp Rheumatol. 2019; 37: 774-782
        • Kiani A.N.
        • Fang H.
        • Akhter E.
        • et al.
        Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.
        Arthritis Care Res (Hoboken). 2015; 67: 442-446
        • Arida A.
        • Legaki A.I.
        • Kravvariti E.
        • et al.
        PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis.
        Front Cardiovasc Med. 2021; 8: 738764
        • Fang C.
        • Luo T.
        • Lin L.
        Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
        Ann Transl Med. 2018; 6: 452
        • Ferraz-Amaro I.
        • Delgado-Frías E.
        • Hernández-Hernández V.
        • et al.
        Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
        Clin Exp Rheumatol. 2020; 38 (Suppl 125(3)): 18-24
        • de Armas-Rillo L.
        • Quevedo-Abeledo J.C.
        • de Vera-González A.
        • et al.
        Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
        Rheumatology (Oxford). 2021; 60: 2296-2306
        • Ferraz-Amaro I.
        • López-Mejías R.
        • Ubilla B.
        • et al.
        Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
        Clin Exp Rheumatol. 2016; 34: 1013-1019
        • Liu A.
        • Rahman M.
        • Hafström I.
        • et al.
        Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
        Lupus. 2020; 29: 825-835
        • Goodson N.J.
        • Symmons D.P.
        • Scott D.G.
        • et al.
        Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort.
        Arthritis Rheum. 2005; 52: 2293-2299
        • Innala L.
        • Möller B.
        • Ljung L.
        • et al.
        Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.
        Arthritis Res Ther. 2011; 13: R131
        • Wållberg-Jonsson S.
        • Johansson H.
        • Ohman M.L.
        • et al.
        Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.
        J Rheumatol. 1999; 26: 2562-2571
        • Shen J.
        • Shang Q.
        • Wong C.K.
        • et al.
        IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study.
        Semin Arthritis Rheum. 2015; 45: 18-27
        • López-Mejías R.
        • Genre F.
        • Remuzgo-Martínez S.
        • et al.
        Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients.
        PLoS One. 2015; 10: e0143153
        • Verma I.
        • Krishan P.
        • Syngle A.
        Predictors of Atherosclerosis in Ankylosing Spondylitis.
        Rheumatol Ther. 2015; 2: 173-182
        • Garg N.
        • Krishan P.
        • Syngle A.
        Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function.
        Int J Angiol. 2016; 25: 222-228
        • Shen J.
        • Shang Q.
        • Wong C.K.
        • et al.
        Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2.
        Sci Rep. 2016; 6: 32116